Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of Bexmarilimab Plus Pembrolizumab for Patients With Advanced (Inoperable or Metastatic) Non-small Cell Lung Cancer (NSCLC)

NCT05171062 is registered in ClinicalTrials.gov with The University of Texas Health Science Center at San Antonio as lead sponsor.

NCT NCT05171062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05171062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of Bexmarilimab Plus Pembrolizumab for Patients With Advanced (Inoperable or Metastatic) Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
The University of Texas Health Science Center at San Antonio
Phase
Phase 1
Overall status
Withdrawn
Start date
June 30, 2023
Completion date
December 31, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer